Ab Science Sa · EURONEXT:AB
Ab Science Sa — Investor Presentation (2018)
17 slides from Ab Science Sa's investor presentation, Oct 4, 2018
Slide 1: Current Status and Perspective for 2018
CURRENT STATUS AND PERSPECTIVE FOR 2018
Slide 2: Disclaimer
Disclaimer This presentation, together with the material set forth herein, does not constitute an offer of securities for sale nor the solicitation of an offer to purchase securities in any jurisdiction. Distribution of such presentation in certain jurisdiction may constitute a breach of applicable
Slide 3: Overview of AB Science
Overview of AB Science AB Science is a late stage development company with rich proprietary drugs pipeline Company overview Leadership Team Alain Moussy (Founder and CEO) Founded in 2001 and has 125 employees – Engineer (ENSTA), and MBA Wharton Headquartered in Paris with a subsidiary in the USA (Ne
Slide 4: GCP Compliance
GCP Compliance
Slide 5: New Organization
New Organization AB Science has completely reorganized its clinical development department, with the appointment of 6 new highly experienced professionals. Creation of new position and appointment of Jean-Pierre Lehner as Scientific Senior Vice-President Responsibility : Reporting to CEO, in charge
Slide 6: GCP status
GCP status As a result of the preventive and corrective actions that have been implemented, AB Science expects GCP clinical hold to be lifted. Upgrading of the Pharmacovigilance system Re-evaluated safety data – Remonitored 80% of all studies, sites, patients visits to ensure that no adverse events
Slide 7: Clinical Data
Clinical Data
Slide 8: ALS – Masitinib in Amyotrophic Lateral Sclerosis
ALS –Masitinib in Amyotrophic Lateral Sclerosis The mechanism of action of masitinib in ALS is based on the targeting of mast cells and aberrant glial cells and has been published in peer-reviewed journals. 8
Slide 9: Masitinib in Amyotrophic Lateral Sclerosis
Masitinib in Amyotrophic Lateral Sclerosis The phase 2/3 study in ALS was positive. An application for conditional marketing authorization was filed at EMA. Trial design Commentary Double blind, placebo controlled, Phase 2/3 study Three treatment arms: 4.5mg/kg/day; 3mg/kg/day; placebo + riluzole “W
Slide 10: Masitinib in Amyotrophic Lateral Sclerosis
Masitinib in Amyotrophic Lateral Sclerosis The design of the confirmatory phase 3 has been optimized based on the results of the first phase 2/3 to increase the treatment effect of masitinib. Optimization on the design of the confirmatory trial Enrolment of patients with shorter disease duration (18
Slide 11: Masitinib in ALS: IP rights
Masitinib in Amyotrophic Lateral Sclerosis IP rights for Masitinib for ALS are secured until 2028 and potentially until 2036 based on a recently filed phase 3 patent. Duration of Protection Status protection Patent on Composition of matter has been filed and delivered. It will be further extended Co
Slide 12: Masitinib in Mastocytosis
Masitinib in Mastocytosis The phase 3 study in severely symptomatic indolent or smoldering systemic mastocytosis was positive. Efficacy resultsininsevere Efficacy results severe indolent indolent systemic systemic mastocytosis mastocytosis (Phase (Phase 3; n=129 3; n=135 patients) patients) Results
Slide 13: Masitinib in progressive form of Multiple sclerosis
Masitinib in progressive form of Multiple sclerosis Based on interim analysis, IDMC recommended the continuation of the masitinib phase 3 study in progressive forms of multiple sclerosis with no requirement to increase the study sample size. Targeted population Progressive forms of multiple sclerosi
Slide 14: New compound AB8939
New compound AB8939 AB Science has developed a new drug candidate targeting microtubules 100x time more potent than doxorubicine and capable of overcoming multidrug resistance. Drug profile AB8939 is new strong microtubule-destabilising drug. - AB8939 induces, early, irreversible and at as low as 10
Slide 15: Perspectives for 2018
Perspectives for 2018
Slide 16: Clinical Newsflow in 2018
Clinical Newsflow in 2018 10 important events are expecting in 2018, including regulatory decision in ALS, 1 phase 3 final result, 3 phase 3 interim results, and the launch of a new compound into clinical development. Timing * Newsflow Therapeutic Area REGULATORY MILESTONE WITH MASITINIB Q2 2018 Apr
Slide 17: Financial
Financial AB Science has cash until end 2019. Cash as of end S1 2017: 49 M€ Cash as of end S2 2017 : 39 M€ Cash burn anticipated for 2018 / 2019 : 41 M€ Equity line in place with CACIB (Credit Agricole Investment Banking) : 2 819 909 Warrant convertible into shares 17